Sernova Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investor Conference

Core Insights - Sernova Biotherapeutics is participating in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, highlighting its focus on regenerative medicine for type 1 diabetes [1][2] Company Overview - Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics, specifically its Cell Pouch Bio-hybrid Organ, aimed at treating type 1 diabetes (T1D) [3] - The company collaborates with Evotec to integrate human donor cells or stem-cell derived islet-like clusters with its Cell Pouch to create bio-hybrid organs [3] - The innovative approach of bio-hybrid organs combines non-biomaterials with living tissues to restore or enhance organ function, initially targeting chronic diseases like T1D and thyroid disorders [3]